$NEOS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Neos Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Neos Therapeutics, Inc.. Get notifications about new insider transactions in Neos Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Option Exercise | D | 1.49 | 115,000 | 171,350 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Option Exercise | D | 3.14 | 150,000 | 471,000 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Sell | D | 0.00 | 83,015 | 0 | 0 | 83 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Robinson James A. Jr. | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Robinson James A. Jr. | Director | Option Exercise | D | 2.03 | 12,500 | 25,375 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Robinson James A. Jr. | Director | Sell | D | 0.00 | 23,453 | 0 | 0 | 23.5 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | D | 2.31 | 65,447 | 151,183 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | D | 5.55 | 100,000 | 555,000 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | D | 1.49 | 395,000 | 588,550 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | D | 2.31 | 392,688 | 907,109 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | D | 6.20 | 600,000 | 3,720,000 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Sell | D | 0.00 | 270,171 | 0 | 0 | 270.2 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | D | 6.05 | 22,756 | 137,674 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | D | 7.65 | 18,322 | 140,163 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | D | 9.63 | 14,777 | 142,303 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | D | 19.82 | 12,500 | 247,750 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Sell | D | 0.00 | 23,453 | 0 | 0 | 23.5 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | D | 6.05 | 22,756 | 137,674 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | D | 7.65 | 18,322 | 140,163 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | D | 9.63 | 14,777 | 142,303 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | D | 10.73 | 12,500 | 134,125 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Sell | D | 0.00 | 23,453 | 0 | 0 | 23.5 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | D | 6.05 | 22,756 | 137,674 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | D | 7.65 | 18,322 | 140,163 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | D | 9.63 | 14,777 | 142,303 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | D | 15.00 | 12,500 | 187,500 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Sell | D | 0.00 | 24,953 | 0 | 0 | 25 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Option Exercise | D | 6.05 | 22,756 | 137,674 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Option Exercise | D | 8.40 | 12,500 | 105,000 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Sell | D | 0.00 | 23,453 | 0 | 0 | 23.5 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | D | 6.05 | 22,756 | 137,674 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | D | 7.65 | 18,322 | 140,163 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | D | 9.63 | 14,777 | 142,303 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | D | 15.00 | 12,500 | 187,500 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | D | 9.32 | 10,416 | 97,077 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Sell | D | 0.00 | 79,130 | 0 | 0 | 79.1 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | D | 1.44 | 46,907 | 67,546 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | D | 6.05 | 22,756 | 137,674 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | D | 7.65 | 18,322 | 140,163 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | D | 9.63 | 14,777 | 142,303 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | D | 15.00 | 12,500 | 187,500 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Sell | D | 0.00 | 446,819 | 0 | 0 | 446.8 K to 0 (-100.00 %) |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 1.49 | 115,000 | 171,350 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 2.31 | 230,276 | 531,938 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 8.30 | 56,250 | 466,875 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 7.00 | 45,000 | 315,000 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 10.74 | 50,000 | 537,000 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 25.50 | 60,230 | 1,535,865 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 9.32 | 12,500 | 116,500 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | D | 2.91 | 86,167 | 250,746 | 0 | |
Mar 19 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Sell | D | 0.00 | 126,245 | 0 | 0 | 126.2 K to 0 (-100.00 %) |
Mar 16 2021 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Payment of Exercise | F | 0.84 | 44,329 | 37,414 | 270,171 | 314.5 K to 270.2 K (-14.10 %) |
Mar 16 2021 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Payment of Exercise | F | 0.84 | 16,985 | 14,335 | 83,015 | 100 K to 83 K (-16.98 %) |
Mar 16 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Payment of Exercise | F | 0.84 | 14,825 | 12,512 | 126,245 | 141.1 K to 126.2 K (-10.51 %) |
Mar 16 2021 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Payment of Exercise | F | 0.88 | 1,390 | 1,227 | 141,070 | 142.5 K to 141.1 K (-0.98 %) |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Grant | A | 0.00 | 23,453 | 0 | 23,453 | 0 to 23.5 K |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Grant | A | 0.00 | 23,453 | 0 | 23,453 | 0 to 23.5 K |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Grant | A | 0.00 | 23,453 | 0 | 79,130 | 55.7 K to 79.1 K (+42.12 %) |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | Robinson James A. Jr. | Director | Grant | A | 0.00 | 23,453 | 0 | 23,453 | 0 to 23.5 K |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Grant | A | 0.00 | 23,453 | 0 | 446,819 | 423.4 K to 446.8 K (+5.54 %) |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Grant | A | 0.00 | 23,453 | 0 | 23,453 | 0 to 23.5 K |
Jun 11 2020 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Grant | A | 0.00 | 23,453 | 0 | 24,953 | 1.5 K to 25 K (+1,563.53 %) |
Mar 16 2020 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | A | 2.31 | 65,447 | 151,183 | 65,447 | |
Mar 16 2020 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | A | 5.55 | 100,000 | 555,000 | 100,000 | |
Mar 04 2020 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Option Exercise | A | 1.49 | 115,000 | 171,350 | 115,000 | |
Mar 04 2020 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Grant | A | 0.00 | 100,000 | 0 | 100,000 | 0 to 100 K |
Mar 04 2020 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | A | 1.49 | 395,000 | 588,550 | 395,000 | |
Mar 04 2020 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Grant | A | 0.00 | 290,000 | 0 | 314,500 | 24.5 K to 314.5 K (+1,183.67 %) |
Mar 04 2020 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | A | 1.49 | 115,000 | 171,350 | 115,000 | |
Mar 04 2020 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Grant | A | 0.00 | 100,000 | 0 | 0 | -100,000 to 0 (-100.00 %) |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | Robinson James A. Jr. | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Jun 17 2019 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | A | 1.44 | 46,907 | 67,546 | 46,907 | |
Mar 22 2019 | NEOS | Neos Therapeutics, ... | Limongelli John M | SVP & General Couns ... | Option Exercise | A | 3.14 | 150,000 | 471,000 | 150,000 | |
Mar 04 2019 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | A | 2.31 | 523,583 | 1,209,477 | 523,583 | |
Mar 04 2019 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | A | 2.31 | 230,276 | 531,938 | 230,276 | |
Jan 30 2019 | NEOS | Neos Therapeutics, ... | Robinson James A. Jr. | Director | Option Exercise | A | 2.03 | 12,500 | 25,375 | 12,500 | |
Dec 13 2018 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Buy | P | 2.16 | 5,000 | 10,820 | 42,460 | 37.5 K to 42.5 K (+13.35 %) |
Dec 10 2018 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Buy | P | 2.11 | 17,097 | 36,119 | 24,500 | 7.4 K to 24.5 K (+230.95 %) |
Dec 07 2018 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Buy | P | 2.04 | 7,403 | 15,120 | 7,403 | 0 to 7.4 K |
Nov 08 2018 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Buy | P | 2.30 | 43,478 | 99,999 | 423,366 | 379.9 K to 423.4 K (+11.44 %) |
Jul 03 2018 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | A | 6.05 | 22,756 | 137,674 | 22,756 | |
Jul 03 2018 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | A | 6.05 | 22,756 | 137,674 | 22,756 | |
Jul 03 2018 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Option Exercise | A | 6.05 | 22,756 | 137,674 | 22,756 | |
Jul 03 2018 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | A | 6.05 | 22,756 | 137,674 | 22,756 | |
Jul 03 2018 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | A | 6.05 | 22,756 | 137,674 | 22,756 | |
Jun 28 2018 | NEOS | Neos Therapeutics, ... | McLaughlin Gerald W. | Chief Executive Off ... | Option Exercise | A | 6.20 | 600,000 | 3,720,000 | 600,000 | |
May 02 2018 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Payment of Exercise | F | 8.30 | 886 | 7,354 | 35,864 | 36.8 K to 35.9 K (-2.41 %) |
May 01 2018 | NEOS | Neos Therapeutics, ... | Szyper Linda M | Director | Option Exercise | A | 8.40 | 12,500 | 105,000 | 12,500 | |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Option Exercise | A | 8.30 | 56,250 | 466,875 | 56,250 | |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Grant | A | 0.00 | 18,750 | 0 | 36,750 | 18 K to 36.8 K (+104.17 %) |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | Engelking Dorothy | VP, Regulatory Affa ... | Option Exercise | A | 8.30 | 11,250 | 93,375 | 11,250 | |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | Engelking Dorothy | VP, Regulatory Affa ... | Grant | A | 0.00 | 3,750 | 0 | 10,416 | 6.7 K to 10.4 K (+56.26 %) |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Option Exercise | A | 8.30 | 75,000 | 622,500 | 75,000 | |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 160,748 | 135.7 K to 160.7 K (+18.42 %) |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | A | 8.30 | 56,250 | 466,875 | 56,250 | |
Mar 05 2018 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Grant | A | 0.00 | 18,750 | 0 | 37,460 | 18.7 K to 37.5 K (+100.21 %) |
Oct 17 2017 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Payment of Exercise | F | 8.00 | 14,895 | 119,160 | 135,748 | 150.6 K to 135.7 K (-9.89 %) |
May 02 2017 | NEOS | Neos Therapeutics, ... | Engelking Dorothy | VP, Regulatory Affa ... | Option Exercise | A | 7.00 | 18,750 | 131,250 | 18,750 | |
May 02 2017 | NEOS | Neos Therapeutics, ... | Engelking Dorothy | VP, Regulatory Affa ... | Grant | A | 0.00 | 6,250 | 0 | 6,666 | 416 to 6.7 K (+1,502.40 %) |
May 02 2017 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | A | 7.00 | 45,000 | 315,000 | 45,000 | |
May 02 2017 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Grant | A | 0.00 | 15,000 | 0 | 18,710 | 3.7 K to 18.7 K (+404.31 %) |
May 02 2017 | NEOS | Neos Therapeutics, ... | Martens Juergen | Chief Tech/Operatio ... | Option Exercise | A | 7.00 | 45,000 | 315,000 | 45,000 | |
May 02 2017 | NEOS | Neos Therapeutics, ... | Martens Juergen | Chief Tech/Operatio ... | Grant | A | 0.00 | 15,000 | 0 | 25,000 | 10 K to 25 K (+150.00 %) |
May 02 2017 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Option Exercise | A | 7.00 | 75,000 | 525,000 | 75,000 | |
May 02 2017 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Grant | A | 0.00 | 25,000 | 0 | 150,643 | 125.6 K to 150.6 K (+19.90 %) |
May 02 2017 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Option Exercise | A | 7.00 | 45,000 | 315,000 | 45,000 | |
May 02 2017 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Grant | A | 0.00 | 15,000 | 0 | 18,000 | 3 K to 18 K (+500.00 %) |
Oct 18 2016 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Payment of Exercise | F | 6.37 | 9,709 | 61,846 | 125,643 | 135.4 K to 125.6 K (-7.17 %) |
Oct 04 2016 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Option Exercise | A | 10.74 | 62,500 | 671,250 | 87,500 | |
Aug 31 2016 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Buy | P | 6.54 | 1,500 | 9,810 | 1,500 | 0 to 1.5 K |
Aug 25 2016 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Buy | P | 6.82 | 3,710 | 25,284 | 3,710 | 0 to 3.7 K |
Jul 05 2016 | NEOS | Neos Therapeutics, ... | Edick Paul R | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
Jul 05 2016 | NEOS | Neos Therapeutics, ... | Fong Bryant | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
Jul 05 2016 | NEOS | Neos Therapeutics, ... | Hecht Beth | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
Jul 05 2016 | NEOS | Neos Therapeutics, ... | Schmid John P. | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
Jul 05 2016 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
Jul 05 2016 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Option Exercise | A | 9.63 | 14,777 | 142,303 | 14,777 | |
Jun 14 2016 | NEOS | Neos Therapeutics, ... | Martens Juergen | Chief Tech/Operatio ... | Buy | P | 9.90 | 10,000 | 99,000 | 10,000 | 0 to 10 K |
Jun 01 2016 | NEOS | Neos Therapeutics, ... | Martens Juergen | Chief Tech/Operatio ... | Option Exercise | A | 10.96 | 150,000 | 1,644,000 | 150,000 | |
May 19 2016 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Buy | P | 7.56 | 3,000 | 22,671 | 3,000 | 0 to 3 K |
May 19 2016 | NEOS | Neos Therapeutics, ... | HELLER ALAN L | Director | Buy | P | 7.61 | 10,000 | 76,100 | 379,888 | 369.9 K to 379.9 K (+2.70 %) |
May 19 2016 | NEOS | Neos Therapeutics, ... | ROBITAILLE GREGORY J | Director | Buy | P | 7.55 | 7,442 | 56,150 | 55,677 | 48.2 K to 55.7 K (+15.43 %) |
Apr 01 2016 | NEOS | Neos Therapeutics, ... | Engelking Dorothy | VP, Regulatory Affa ... | Option Exercise | A | 10.74 | 15,000 | 161,100 | 15,000 | |
Apr 01 2016 | NEOS | Neos Therapeutics, ... | McDonnell Thomas P | Chief Commercial Of ... | Option Exercise | A | 10.74 | 50,000 | 537,000 | 50,000 | |
Apr 01 2016 | NEOS | Neos Therapeutics, ... | Eisenstadt Richard I | Chief Financial Off ... | Option Exercise | A | 10.74 | 50,000 | 537,000 | 50,000 | |
Apr 01 2016 | NEOS | Neos Therapeutics, ... | Garg Vipin K | Chief Executive Off ... | Option Exercise | A | 10.74 | 100,000 | 1,074,000 | 100,000 | |
Apr 20 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 9.88 | 213 | 2,105 | 39,998 | 40.2 K to 40 K (-0.53 %) |
Apr 20 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.03 | 182 | 1,825 | 40,211 | 40.4 K to 40.2 K (-0.45 %) |
Apr 20 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.10 | 114 | 1,151 | 40,393 | 40.5 K to 40.4 K (-0.28 %) |
Apr 20 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 9.88 | 8,327 | 82,305 | 1,559,995 | 1.6 M to 1.6 M (-0.53 %) |
Apr 20 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.03 | 7,097 | 71,176 | 1,568,322 | 1.6 M to 1.6 M (-0.45 %) |
Apr 20 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.10 | 4,434 | 44,782 | 1,575,419 | 1.6 M to 1.6 M (-0.28 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.32 | 180 | 1,857 | 40,507 | 40.7 K to 40.5 K (-0.44 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.13 | 275 | 2,785 | 40,687 | 41 K to 40.7 K (-0.67 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.32 | 325 | 3,353 | 40,962 | 41.3 K to 41 K (-0.79 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.27 | 352 | 3,614 | 41,287 | 41.6 K to 41.3 K (-0.85 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.16 | 317 | 3,221 | 41,639 | 42 K to 41.6 K (-0.76 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.32 | 7,020 | 72,430 | 1,579,853 | 1.6 M to 1.6 M (-0.44 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.13 | 10,735 | 108,697 | 1,586,873 | 1.6 M to 1.6 M (-0.67 %) |
Apr 15 2016 | NEOS | Neos Therapeutics, ... | Presidio Partners 2007, L.P. | 10% Owner | Sell | S | 10.32 | 12,675 | 130,783 | 1,597,608 | 1.6 M to 1.6 M (-0.79 %) |